Abstract:Discovery and validation of peripheral immune biomarkers are critical for improved prediction and prognostication of clinical outcomes for patients with solid tumours in response to immune checkpoint inhibition. Many candidate peripheral biomarkers, including cytokines, soluble factors, and immune cells have the potential as biomarkers to guide immunotherapy of solid tumours. Integration of multiple peripheral immune parameters may improve prediction and prognostication. Critical work in all phases of the biomarker discovery, validation, and standardization process is required to realize the potential of peripheral immune biomarkers to guide immunotherapy. Background With the rapid adoption of immunotherapy for the treatment of cancer comes the pressing need for readily accessible biomarkers to guide immunotherapeutic strategies and offer insights into outcomes with specific treatments. Regular sampling of solid tumour tissues outside of melanoma for immune monitoring is not often feasible; conversely, routine, frequent interrogation of circulating immune biomarkers is entirely possible. As immunotherapies and immune checkpoint inhibitors, in particular, are more widely used in first‐line, neoadjuvant, and metastatic settings, the discovery and validation of peripheral immune biomarkers are urgently needed across solid tumour types for improved prediction and prognostication of clinical outcomes in response to immunotherapy, as well as elucidation of mechanistic underpinnings of the intervention. Careful experimental design, encompassing both retrospective and prospective studies, is required in such biomarker identification studies, and concerted efforts are essential for their advancement into clinical settings. Conclusion In this review, we summarize shared immune features between the tumour microenvironment and systemic circulation, evaluate exploratory peripheral immune biomarker studies, and discuss associations between candidate biomarkers with clinical outcomes. We also consider integration of multiple peripheral immune parameters for better prediction and prognostication and discuss considerations in study design to further evaluate the clinical utility of candidate peripheral immune biomarkers for immunotherapy of solid tumours. Highlights Peripheral immune biomarkers are critical for improved prediction and prognostication of clinical outcomes for patients with solid tumours treated with immune checkpoint inhibition. Candidate peripheral biomarkers, such as cytokines, soluble factors, and immune cells, have potential as biomarkers to guide immunotherapy of solid tumours. Multiple peripheral immune parameters may be integrated to improve prediction and prognostication. The potential of peripheral immune biomarkers to guide immunotherapy of solid tumours requires critical work in biomarker discovery, validation, and standardization.

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications

Soluble immune checkpoints in cancer: production, function and biological significance

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Soluble immune-checkpoint factors: a potential immunotherapy biomarker

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers

Soluble Immune Checkpoint-Related Proteins As Predictors of Tumor Recurrence, Survival, and T Cell Phenotypes in Clear Cell Renal Cell Carcinoma Patients

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune checkpoint inhibitors: recent progress and potential biomarkers

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors

A comprehensive profiling of soluble immune checkpoints from the sera of patients with non‐small cell lung cancer

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

Advances and prospects of biomarkers for immune checkpoint inhibitors